• News
  • North America

Frazier Healthcare Partners Completes ATUM Majority Investment

Frazier takes majority stake in ATUM, a bioengineering partner to biopharma companies.

11/17/2026
•Ghita Khalfaoui
Back to News

Frazier Healthcare Partners completed a majority investment in ATUM. The firm has raised more than $11 billion for private funds and co-investment opportunities. ATUM provides bioengineering tools that help biopharma companies advance next-generation biotherapeutics.


Deal and leadership

Frazier completed the deal alongside co-investors, including Frazier Life Sciences. ATUM's existing founders and management team also participated. Frazier Executive in Residence Milton Boyer will join the board as executive chair, and Jeremy Minshull will continue as CEO.

Company background

ATUM began as DNA2.0 in 2003. It pioneered bioengineering work in gene design, protein optimization, and cell line development. The company is based in Newark, California, and serves biopharma customers worldwide.

What ATUM provides

ATUM's platform integrates machine learning algorithms, advanced gene synthesis, and high-performance cell line development. It helps biopharma innovators overcome difficult expression and manufacturing hurdles. The solutions are designed to reduce risks and shorten drug development timelines.


ATUM plans to expand capacity, grow infrastructure, and speed up innovation under the new partnership. Frazier will contribute its Center of Excellence, Executive in Residence program, and life sciences expertise. Baird and Paul Hastings advised ATUM, and William Blair and Goodwin Procter advised Frazier.